Business
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Applica
About this update from Unicycive Therapeutics, Inc.
[{"type":"image","alt":"Unicycive Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Unicycive Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":179,"url":"https://media.zenfs.com/en/globenewswire.com/2d40894933970b803051237eb449f48e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DpoKkm2ybOJn1WoJKEgy0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2d40894933970b803051237eb449f48e","width":300,"height":179}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"DA assigns Prescription Drug User Fee Act (PDUFA) target date of June 27, 2026","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027","length":80,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":158,"olType":false},{"type":"text","content":"LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The Agency has deemed the OLC resubmission to be a Class II complete response which has a six-month review period from the date of resubmission and set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2026.","length":770,"tagName":"p"},{"type":"text","content":"“We are pleased that the agency has promptly accepted the resubmission of our NDA for OLC,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “We are advancing our commercial preparation activities in anticipation of a potential launch of OLC later this year, to help provide an important treatment option to patients with chronic kidney disease (CKD) on dialysis who continue to struggle with hyperphosphatemia.”","length":427,"tagName":"p"},{"type":"text","content":"The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volun...